Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,125,628
  • Shares Outstanding, K 58,535
  • Annual Sales, $ 680 K
  • Annual Income, $ -201,590 K
  • 60-Month Beta 0.71
  • Price/Sales 1,615.68
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHAT with:

Options Overview Details

View History
  • Implied Volatility 87.66% ( +5.61%)
  • Historical Volatility 59.78%
  • IV Percentile 23%
  • IV Rank 27.09%
  • IV High 215.46% on 10/27/23
  • IV Low 40.17% on 09/12/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 61
  • Volume Avg (30-Day) 170
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 4,965
  • Open Int (30-Day) 4,727

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.57
  • Number of Estimates 2
  • High Estimate -1.51
  • Low Estimate -1.62
  • Prior Year -0.76
  • Growth Rate Est. (year over year) -106.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.25 +54.37%
on 08/20/24
19.67 -3.89%
on 09/12/24
+6.02 (+46.70%)
since 08/19/24
3-Month
9.82 +92.62%
on 07/02/24
19.67 -3.89%
on 09/12/24
+7.04 (+59.31%)
since 06/18/24
52-Week
6.07 +211.79%
on 02/13/24
19.67 -3.89%
on 09/12/24
+7.83 (+70.67%)
since 09/19/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches...

PHAT : 18.65 (-3.02%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches...

PHAT : 18.65 (-3.02%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 18.65 (-3.02%)
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT)...

PHAT : 18.65 (-3.02%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 18.65 (-3.02%)
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT)...

PHAT : 18.65 (-3.02%)
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated...

PHAT : 18.65 (-3.02%)
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws

/PRNewswire/ -- Attention Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) shareholders: The Law Offices of Vincent Wong announce that an investigation...

PHAT : 18.65 (-3.02%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 18.65 (-3.02%)
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated...

PHAT : 18.65 (-3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 20.97
2nd Resistance Point 20.25
1st Resistance Point 19.74
Last Price 18.65
1st Support Level 18.51
2nd Support Level 17.80
3rd Support Level 17.29

See More

52-Week High 19.67
Last Price 18.65
Fibonacci 61.8% 14.48
Fibonacci 50% 12.87
Fibonacci 38.2% 11.26
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar